Ruolo dell'interferon in corso di cirrosi epatica compensata HCV correlata

Translated title of the contribution: HCV compensated cirrhosis: Role of interferon therapy

Gianni Testino, Fabio De Iaco, Gianluigi Ravetti, Carlo Ferro, Enzo Andorno, Umberto Valente

Research output: Contribution to journalArticle

Abstract

It is well known that a high proportion of patients with compensated cirrhosis (Child-Pugh A) remain so far many years. Once clinical decompensation has occoured, the prognosis is very poor. There is growing evidence that the use of Interferon (IFN) as a therapy for chronic hepatitis C may slaken the natural history of the pathology. The use of IFN in viral cirrhosis is controversial with respect to its effectiveness. We conducted a trial with IFN (59 patients, average age: 55.3 ± 7) vs no therapy (71 patients, average age: 56.8 ± 8) in HCV compensated cirrhosis with abnormal ALT and HCV-RNA positive serum to investigate the incidence of negative events: clinical-laboratoristic worsening (Child B or C, death, orthotopic liver transplantation) or hepatocellular carcinoma (HCC) (mean follow-up 96 ± 18.3 months). In the treated patients the negative events altogether evaluated were present in 45% of cases, in non treated patients in 88.7%. In particular, in the non-treated group the cases with clinical-laboratoristic worsening are higher even as regards the treated ones, independently from the type of response. IFN therapy does not reduce the risk of HCC. It can be concluded that the therapy with IFN can be effective in reducing the possibility of the passage from Child A to Child B or C, of death and of liver transplantation.

Translated title of the contributionHCV compensated cirrhosis: Role of interferon therapy
Original languageItalian
Pages (from-to)242-246
Number of pages5
JournalInternista
Volume10
Issue number4
Publication statusPublished - Dec 2002

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'HCV compensated cirrhosis: Role of interferon therapy'. Together they form a unique fingerprint.

  • Cite this

    Testino, G., De Iaco, F., Ravetti, G., Ferro, C., Andorno, E., & Valente, U. (2002). Ruolo dell'interferon in corso di cirrosi epatica compensata HCV correlata. Internista, 10(4), 242-246.